Alle Storys
Keine Story von Eisai Co. Ltd. mehr verpassen.

Eisai Co. Ltd.

Eisai Signs Exclusive Agreement to Commercialize NeuroBloc(R) for Europe

Tokyo (ots/PRNewswire)

Eisai Co., Ltd. (Headquarters: Tokyo,
President & CEO: Haruo Naito)  announced that the company has signed
on May 14, 2007 (the U.S. Eastern Time)  the exclusive agreement with
Solstice Neurosciences, Inc. (Headquarters:  Pennsylvania, U.S.,
President & CEO: Shawn Patrick O'Brien) for NeuroBloc(R)  , an
injectable form of botulinum toxin type B agent owned by Solstice. In
this new agreement, Eisai gained the commercialization right over a
total of  35 European countries, including the 27 EU countries,
Norway, Iceland,  Liechtenstein, Monaco, Switzerland, Croatia,
Turkey, and Russia.
NeuroBloc(R) was approved for Cervical Dystonia through the
centralized  procedure by the European Medicines Evaluation Agency
(EMEA) in January 2001  and has been made available in eight European
countries so far. Treatment  with NeuroBloc(R) interrupts cholinergic
transmission between nerves and the  affected muscle, causing it to
For the Japanese Market, Eisai signed an exclusive agreement with
Elan  Corporation, plc.(x) for the development and marketing right of
this product  in September 2000. In December 2006, Eisai filed the
new drug application for  this product in Japan for the treatment of
Cervical Dystonia.
Eisai is rapidly enhancing its neurology product lineup in Europe
with its global products including Aricept(R) (symptomatic treatment
of Alzheimer's disease) as well as the anti-epilepsy agents
Zonegran(R) and Inovelon(R). With this strategic alliance for
NeuroBloc(R), Eisai expects to make further contributions to
increasing the benefits to the patients and their families in Europe.
(x) Elan Corporation, plc. sold all assets of NeuroBloc(R) to
Solstice Neurosciences, Inc. in July 2004.
Notes to Editor:
About Cervical Dystonia
Cervical Dystonia is a condition of abnormal muscle tone and
movement  that can result in painful abnormalities of posture or
inability to flex and  relax affected neck and shoulder muscles. The
botulinum toxin type B compound  is effective in the treatment of
cervical dystonia by relaxing affected neck  and shoulder muscles
through blocking the neurotransmitter acetylcholine in  those
patients responsive to botulinum toxin therapy treatment.
    Andrew Day
    European Director of PR and Communications
    Eisai Europe Limited
    Tel: +44(0)-208-600-1400


Contact: Andrew Day, European Director of PR and Communications,
Eisai Europe Limited, Tel: +44(0)-208-600-1400

Weitere Storys: Eisai Co. Ltd.
Weitere Storys: Eisai Co. Ltd.
  • 22.03.2007 – 16:57

    Eisai to Acquire Morphotek

    Tokyo, Japan, Woodcliff Lake, New Jersey and Exton, Pennsylvania (ots/PRNewswire) - - Eisai's Dramatic Leap Towards Biologic Therapeutics Evidenced by the Acquisition Eisai Co., Ltd. (Tokyo, "Eisai", President and CEO: Haruo Naito), Eisai Corporation of North America (Woodcliff Lake, NJ, "ECA", President: Hajime Shimizu) and Morphotek(R) Inc. (Exton, PA, "Morphotek", CEO: Nicholas Nicolaides) today announce that ECA has signed a definitive agreement to acquire ...

  • 16.03.2006 – 07:04

    Eisai Reports Results from Latest Donepezil Study in Vascular Dementia

    Tokyo, Japan (ots/PRNewswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) today announced preliminary results from the latest donepezil (Product name: ARICEPT(R)) study (Study 319) on the treatment of people with vascular dementia (VaD). Preliminary efficacy results show that those who received donepezil improved on measures of cognition, ...